Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Lipocine Inc.

NASDAQ: LPCN · Life Sciences · 10 alerts · CIK 1535955

Share price
$1.66Close, Nov 16
Market cap
$18.4M
Shares outstanding
11.07MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Lipocine Inc. filings on SEC EDGAR ↗

9:36 AM ET 8-K
Financial Results

Lipocine Financial Results

Lipocine Inc. reported financial results for the third quarter of 2026, highlighting a net loss of $0.7 million and a cash position of $21.5 million as of September 30, 2026. The company also provided clinical updates, including the initiation of the Phase 3 BLOOM study for LPCN 1154 (BRLIZIO) in postpartum depression and the approval of TLANDO in Canada.

Term
Q3 2026
9:31 AM ET 10-Q
Financial Results

Lipocine Q3 2026 Results: Net Loss of $666K, Loss Narrows

Lipocine Inc. reported total revenues of $2.6 million for the nine months ended September 30, 2026, driven by a $2.1 million license fee. Despite the revenue increase, the company incurred a net loss of $7.0 million due to higher operating expenses, though it maintains sufficient capital to fund operations through November 2027.

Key figure
Net loss $666K

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.